Resverlogix Thinks RVX-208 Can Succeed At Reducing Arterial Plaque Where Pfizer's Torcetrapib Failed
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Resverlogix believes its small-molecule drug RVX-208 delivers on a key goal in cardiovascular drug development - the ability to clear life-threatening plaque out of arteries - setting the firm up to succeed with its first-in-class agent where others have failed and to write its own ticket in the $35 billion cholesterol market
You may also be interested in...
Resverlogix Plays Up Importance Of New Study After Missing Phase II Endpoint
Resverlogix Corp. says it is keeping its faith in RVX-208 – a cholesterol drug designed to improve HDL function – despite missing a primary efficacy endpoint in the Phase II ASSERT trial, facing questions over a newly seen liver signal, and suffering a major blow to its stock price.
Resverlogix Plays Up Importance Of New Study After Missing Phase II Endpoint
Resverlogix Corp. says it is keeping its faith in RVX-208 – a cholesterol drug designed to improve HDL function – despite missing a primary efficacy endpoint in the Phase II ASSERT trial, facing questions over a newly seen liver signal, and suffering a major blow to its stock price.
Resverlogix Plays Up Importance Of New Study After Missing Phase II Endpoint
Continuing in its quest for the holy grail of a novel HDL cholesterol drug, Resverlogix maintains that an upcoming Phase IIb trial will test a more appropriate, higher-risk population and study patients longer.